vs
Journey Medical Corp（DERM）与LIGHTPATH TECHNOLOGIES INC（LPTH）财务数据对比。点击上方公司名可切换其他公司
LIGHTPATH TECHNOLOGIES INC的季度营收约是Journey Medical Corp的1.0倍（$16.4M vs $16.1M），Journey Medical Corp净利率更高（-7.8% vs -57.5%，领先49.8%），LIGHTPATH TECHNOLOGIES INC同比增速更快（120.2% vs 27.3%），过去两年LIGHTPATH TECHNOLOGIES INC的营收复合增速更高（45.7% vs 11.0%）
Journey Medical Corp是一家处于商业化阶段的生物制药企业，专注于皮肤病治疗领域，研发、生产并销售处方及非处方皮肤用药，覆盖痤疮、特应性皮炎、皮肤真菌感染等适应症，主要服务美国市场的医疗机构与患者。
LightPath Technologies Inc是一家精密光学组件及组件生产商，主营非球面透镜、红外光学器件、光纤产品等，服务工业自动化、航空航天、国防、医疗成像、电信等领域的全球客户，提供标准及定制化光学解决方案。
DERM vs LPTH — 直观对比
营收规模更大
LPTH
是对方的1.0倍
$16.1M
营收增速更快
LPTH
高出92.9%
27.3%
净利率更高
DERM
高出49.8%
-57.5%
两年增速更快
LPTH
近两年复合增速
11.0%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $16.1M | $16.4M |
| 净利润 | $-1.2M | $-9.4M |
| 毛利率 | — | 36.8% |
| 营业利润率 | -2.8% | -52.6% |
| 净利率 | -7.8% | -57.5% |
| 营收同比 | 27.3% | 120.2% |
| 净利润同比 | -182.0% | -260.1% |
| 每股收益（稀释后） | $-0.04 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DERMLPTH
| Q4 25 | $16.1M | $16.4M | ||
| Q3 25 | $17.0M | $15.1M | ||
| Q2 25 | $15.0M | $12.2M | ||
| Q1 25 | $13.1M | $9.2M | ||
| Q4 24 | $12.6M | $7.4M | ||
| Q3 24 | $14.6M | $8.4M | ||
| Q2 24 | $14.9M | $8.6M | ||
| Q1 24 | $13.0M | $7.7M |
净利润DERMLPTH
| Q4 25 | $-1.2M | $-9.4M | ||
| Q3 25 | $-2.3M | $-2.9M | ||
| Q2 25 | $-3.8M | $-7.1M | ||
| Q1 25 | $-4.1M | $-3.6M | ||
| Q4 24 | $1.5M | $-2.6M | ||
| Q3 24 | $-2.4M | $-1.6M | ||
| Q2 24 | $-3.4M | $-2.4M | ||
| Q1 24 | $-10.4M | $-2.6M |
毛利率DERMLPTH
| Q4 25 | — | 36.8% | ||
| Q3 25 | — | 29.8% | ||
| Q2 25 | — | 22.0% | ||
| Q1 25 | — | 29.1% | ||
| Q4 24 | 82.3% | 26.0% | ||
| Q3 24 | 63.9% | 33.9% | ||
| Q2 24 | 56.0% | 29.2% | ||
| Q1 24 | 47.7% | 20.9% |
营业利润率DERMLPTH
| Q4 25 | -2.8% | -52.6% | ||
| Q3 25 | -9.0% | -16.6% | ||
| Q2 25 | -19.2% | -38.0% | ||
| Q1 25 | -25.3% | -36.3% | ||
| Q4 24 | 17.7% | -33.5% | ||
| Q3 24 | -19.8% | -16.4% | ||
| Q2 24 | -19.7% | -25.6% | ||
| Q1 24 | -77.4% | -33.6% |
净利率DERMLPTH
| Q4 25 | -7.8% | -57.5% | ||
| Q3 25 | -13.6% | -19.2% | ||
| Q2 25 | -25.3% | -57.8% | ||
| Q1 25 | -31.0% | -39.1% | ||
| Q4 24 | 12.1% | -35.2% | ||
| Q3 24 | -16.3% | -19.3% | ||
| Q2 24 | -22.6% | -27.3% | ||
| Q1 24 | -80.1% | -33.7% |
每股收益（稀释后）DERMLPTH
| Q4 25 | $-0.04 | $-0.20 | ||
| Q3 25 | $-0.09 | $-0.07 | ||
| Q2 25 | $-0.16 | $0.19 | ||
| Q1 25 | $-0.18 | $-0.44 | ||
| Q4 24 | $0.10 | $-0.07 | ||
| Q3 24 | $-0.12 | $-0.04 | ||
| Q2 24 | $-0.17 | $-0.15 | ||
| Q1 24 | $-0.53 | $-0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $24.1M | $73.6M |
| 总债务越低越好 | $25.3M | — |
| 股东权益账面价值 | $31.9M | $77.9M |
| 总资产 | $94.6M | $148.6M |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资DERMLPTH
| Q4 25 | $24.1M | $73.6M | ||
| Q3 25 | $24.9M | — | ||
| Q2 25 | $20.3M | $4.9M | ||
| Q1 25 | $21.1M | — | ||
| Q4 24 | $20.3M | — | ||
| Q3 24 | $22.5M | — | ||
| Q2 24 | $23.9M | — | ||
| Q1 24 | $24.1M | — |
总债务DERMLPTH
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | $535.0K | ||
| Q1 24 | $14.7M | $599.4K |
股东权益DERMLPTH
| Q4 25 | $31.9M | $77.9M | ||
| Q3 25 | $25.9M | $21.4M | ||
| Q2 25 | $19.2M | $15.6M | ||
| Q1 25 | $21.5M | $15.7M | ||
| Q4 24 | $20.1M | $26.7M | ||
| Q3 24 | $10.9M | $29.4M | ||
| Q2 24 | $11.3M | $30.2M | ||
| Q1 24 | $13.0M | $31.7M |
总资产DERMLPTH
| Q4 25 | $94.6M | $148.6M | ||
| Q3 25 | $85.2M | $87.3M | ||
| Q2 25 | $81.2M | $81.5M | ||
| Q1 25 | $85.0M | $81.4M | ||
| Q4 24 | $80.2M | $45.8M | ||
| Q3 24 | $64.0M | $48.4M | ||
| Q2 24 | $65.2M | $48.1M | ||
| Q1 24 | $66.6M | $49.7M |
负债/权益比DERMLPTH
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | 0.02× | ||
| Q1 24 | 1.13× | 0.02× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.3M | $2.8M |
| 自由现金流经营现金流 - 资本支出 | — | $2.0M |
| 自由现金流率自由现金流/营收 | — | 12.0% |
| 资本支出强度资本支出/营收 | — | 5.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-6.3M |
8季度趋势，按日历期对齐
经营现金流DERMLPTH
| Q4 25 | $-6.3M | $2.8M | ||
| Q3 25 | $-2.4M | $-1.1M | ||
| Q2 25 | $-942.0K | $-2.6M | ||
| Q1 25 | $-2.8M | $-3.2M | ||
| Q4 24 | $2.2M | $-737.4K | ||
| Q3 24 | $-1.2M | $-1.7M | ||
| Q2 24 | $-5.2M | $64.7K | ||
| Q1 24 | $-5.0M | $-394.2K |
自由现金流DERMLPTH
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $-1.2M | ||
| Q2 25 | — | $-3.3M | ||
| Q1 25 | — | $-3.7M | ||
| Q4 24 | — | $-817.8K | ||
| Q3 24 | — | $-1.8M | ||
| Q2 24 | — | $-225.5K | ||
| Q1 24 | — | $-802.5K |
自由现金流率DERMLPTH
| Q4 25 | — | 12.0% | ||
| Q3 25 | — | -8.1% | ||
| Q2 25 | — | -27.3% | ||
| Q1 25 | — | -40.0% | ||
| Q4 24 | — | -11.0% | ||
| Q3 24 | — | -21.2% | ||
| Q2 24 | — | -2.6% | ||
| Q1 24 | — | -10.4% |
资本支出强度DERMLPTH
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 5.6% | ||
| Q1 25 | — | 4.6% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 3.4% | ||
| Q1 24 | — | 5.3% |
现金转化率DERMLPTH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
LPTH
| Other | $7.9M | 48% |
| Infrared Components | $5.0M | 31% |
| Visible Components | $3.4M | 21% |
